Breaking News, Promotions & Moves

Acelyrin Names Patricia Turney Chief Technical Operations Officer

Brings more than 25 years of biopharmaceutical experience across R&D, clinical and commercial supply management.

Acelyrin Inc., a late-stage clinical biopharma company focused on development and delivery of transformative medicines in immunology, appointed Patricia Turney Chief Technical Operations Officer. Reporting to Founder and CEO Shao-Lee Lin, Turney will be responsible for overseeing technical operations, CMC regulatory, corporate quality and facilities, and will join the company’s Senior Leadership Team.

Turney most recently served as senior vice president of operations at Arcutis Biotherapeutics, Inc., where she built the technical operations organization to successfully execute on their product development milestones including several product filings and the first commercial product launch in the U.S. and Canada. Prior to that, Turney held roles of increasing responsibility with Amgen. As vice president of external manufacturing, she was responsible for a worldwide network of more than fifty contract manufacturing sites and her organization managed early-to-late-stage programs across numerous technologies and delivery platforms.

“I am delighted to welcome Patricia to the Acelyrin leadership team as we continue to advance our portfolio and grow our manufacturing capabilities and capacity,” said Lin. “With a distinguished career and proven track record across both large and small biopharma, her extensive expertise will be pivotal during this important time. I am confident that her leadership will further enhance our efforts in delivering transformative medicines to patients.”

“I am thrilled to be joining Acelyrin under the visionary leadership of Shao-Lee as well as the opportunity to be working alongside such a talented team, especially during this period of rapid growth advancing a robust portfolio featuring multiple large, Phase 3 programs with potential commercialization of transformative medicines to patients worldwide not too far off in the future,” said Turney. “I am eager to contribute to the Acelyrin’s mission and excited to collaborate with my new colleagues to ensure the high-quality standards, and robust technical operations enable the necessary innovative solutions to positively impact patient outcomes.”

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters